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Aim of the study: To evaluate the ef-
ficacy and safety of Yttrium-90 Ibritu-
momab Tiuxetan (90Y-IT) as a consoli-
dation therapy in the management of 
DLBCL. 
Material and methods: Patients with 
primary refractory or high-risk DLBCL 
(n = 18), ineligible for autologous stem-
cell transplantation, were included in 
a  retrospective study performed at 
three centers by the Polish Lymphoma 
Research Group (PLRG). All patients 
(mean age 61, range 35–82) either 
didn’t achieve a complete response or 
didn’t complete the scheduled thera-
py due to its complications. Response 
rates (CR, PR, SD, PD) according to 
Cheson criteria, overall survival (OS), 
progression-free survival (PFS) and ad-
verse effects of radioimmunotherapy 
were analyzed.
Results: Consolidation radioimmuno-
therapy increased the CR rate from 
38% (n = 7) to 82% (n = 15). One pa-
tient remained in PR, one patient re- 
mained in SD, while one patient re-
mained in PD. During a  median fol-
low-up of five years, 11 patients (62%) 
were alive with no recurrence, 4 pa-
tients (22%) were alive with relapse 
while 3 patients (16%) died. There was 
no statistically significant difference 
in PFS between those in CR and those 
in PR before 90Y-IT. 
Conclusions: Radioimmunotherapy is 
an effective consolidation therapy for 
high risk/refractory DLBCL patients 
and worthy of further investigation in 
prospective trials.
Key words: diffuse large B-cell lympho-
ma, radioimmunotherapy, Yttrium-90 
Ibritumomab Tiuxetan, consolidation.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the second most common type 
of lymphoma, accounting for 25–30% of all cases. The incidence of DLBCL 
varies from 5–6/100,000 per year in Europe to 8/100,000 per year in the U.S. 
[1, 2]. Anthracycline-based regimens like CHOP (cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) have been the cornerstone of therapy for 
several decades. Important progress has been made with the introduction 
of a chimeric anti-CD20 monoclonal antibody, rituximab. R-CHOP chemo-
therapy has significantly improved complete response (CR), progression-free 
survival (PFS) and overall survival (OS) rates; hence, it has become the rec-
ommended standard of front-line therapy in DLBCL [3–5]. Nevertheless, re-
lapsing or refractory DLBCL poses a significant problem. The role of high-
dose chemotherapy and autologous stem cell transplant (ASCT) as a part of 
first-line treatment is controversial. ASCT consolidation is a recommended 
standard for chemo-sensitive relapse. When compared with salvage che-
motherapy without a transplant, ASCT consolidation significantly improved 
event-free survival (EFS) and OS (46% vs. 12% and 53% vs. 32%, respectively) 
[6, 7]. Unfortunately, present results of ASCT, in patients treated with ritux-
imab, are worse than those described in the PARMA trial. Despite significant 
progress, patient outcomes in DLBCL remain unsatisfactory. This provides 
ample opportunity for new treatment strategies. New drugs such as lena-
lidomid, bortezomid and bevacizumab, introduced as monotherapy or in 
combination with chemotherapy are being evaluated [8, 9]. Our preliminary 
results suggest a possible role for radioimmunotherapy (Yttrium-90 Ibritu-
momab Tiuxetan) as a consolidation strategy in the management of DLBCL.
Material and methods
Eighteen patients (6 men and 12 women) with histologically confirmed 
CD20+ DLBCL, treated at three PLRG (Polish Lymphoma Research Group) 
centers, were analyzed. All patients (average age 61, range 35–82) either 
didn’t achieve a complete response or didn’t complete the scheduled ther-
apy due to its complications. None of them could have been subjected to 
ASCT consolidation because of age, comorbidities or other limitations. Ra-
dioimmunotherapy (RIT) was used as first-line consolidation in 12 cases 
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(67%), while in 6 cases (33%), it was used after salvage 
therapy for relapsed/refractory DLBCL.
Patients included in the analysis fulfilled classical eligi-
bility criteria for radioimmunotherapy: WHO performance 
status from 0 to 2, bone marrow infiltration of less than 
15%, lymph node diameter measuring less than 5 cm, ab-
solute neutrophil count (ANC) of at least 1.5 × 109/l and 
platelet count of at least 100 × 109/l. Patient characteris-
tics at diagnosis and prior to radioimmunotherapy are pre-
sented in Tables 1 and 2. 
Radioimmunotherapy was performed on an outpatient 
basis and consisted of two subsequent visits. On day 7, 
the rituximab infusion (250 mg/m2) was administered. 
Seven days later, a second dose of rituximab and 90Y-IT 
was injected intravenously for over 10 minutes. The 90Y 
dose (0.4 mCi per kg/14.8 MBq per kg) was conjugated 
with ibritumomab tiuxetan at the Nuclear Medicine labo-
ratory immediately before infusion. 
Overall response rate (ORR) was assessed according to 
Cheson criteria (CR, PR, SD, PD). The mean follow-up dura-
tion after 90Y-IT was three and a half years. Progression-free 
survival (PFS) was defined as time from radioimmunother-
apy initiation to lymphoma progression or death. Overall 
survival (OS) was defined as time from radioimmunother-
apy initiation to death. Radioimmunotherapy side effects 
and exact causes of death were also noted and evaluated. 
Statistical analysis
A statistical analysis was performed using the Statistica 
software suite (ver. 8.0, released in 2007). In order to com-
pare the response before and after radioimmunotherapy, 
a chi-square test with Fisher’s amendment was used. PFS 
and OS were analyzed by the Kaplan-Meier method, using 
Gehan’s Wilcoxon test for comparison. 
Results
Response to therapy
Radioimmunotherapy was administered as a consoli-
dation strategy in patients with a partial response to pre-
ceeding chemotherapy or high-risk cases with a complete 
response. Out of 12 patients consolidated after the end of 
first-line therapy, 4 patients (2 CR and 2 PR) had an ab-
breviated chemotherapy restricted to four R-CHOP cycles 
due to treatment intolerance (two cases of myocardial in-
farction and two cases of severe left ventricular failure), 
5 patients didn’t achieve CR after completion of the first-line 
treatment (4 PR after six cycles, 1 SD after ten cycles), and 
3 patients were regarded high-risk despite CR after eight 
cycles. All six relapsed/refractory cases (consolidated after 
2nd –4th line of therapy) were considered high-risk, although 
two cases achieved CR. After radioimmunotherapy, seven 
cases (38%) remained in CR, a further eight cases (44%) 
were converted from PR to CR, one case (6%) relapsed, one 
case (6%) remained in SD and one case (6%) remained 
in PR. Consolidation radioimmunotherapy increased 
the CR rate from 38% (n = 7) to 82% (n = 15) (Table III). 
RIT consolidation significantly improved the response 
rates, compared to preceding chemotherapy (p = 0.01). 
Survival analysis
At a median follow-up of five years, 11 patients (62%) 
were alive with no recurrence, 4 patients (22%) were alive 
with relapsed/refractory DLBCL and 3 patients (16%) died. 
Two deaths were due to subsequent lymphoma relapse/
resistance (28 and 42 months after diagnosis), while one 
death resulted from transformation to acute myeloid leu-
kemia.
A Kaplan-Meier survival analysis determined the PFS and 
OS at 5 years to be 56% and 82%, respectively (Figs. 1, 2); 
the median PFS and OS had not yet been reached. Radio-
immunotherapy was more effective if administered early 
as a consolidation of first-line therapy. The differences in 
Table 1. Patients’ characteristics (n = 18) at diagnosis
Risk factors Frequency
B Symptoms 13 (72%)
Bulky disease 9 (50%)
Advanced clinical stage III – 4 (22%), IV – 12 (67%)
Bone marrow involvement 9 (50%)
IPI score 3–5 15 (83%)
Table 2. Patients’ characteristics (n = 18) at qualifications to 90Y-IT
Group characteristics Frequency
Bone marrow involvement 3 (17%)
Lymph nodes enlargement > 2 cm 6 (33%)
2–4 prior chemotherapy regimens 6 (33%)
Previous treatment with rituximab 12 (67%)
Table 3. Responses after proceeding chemo(immuno)therapy and 
radioimmunotherapy consolidation 
Response After chemotherapy n (%) After 90Y-IT n (%)
CR 8 (44) 15 (82)
PR 10 (56) 1 (6)
SD 0 1 (6)
PD 0 1 (6)
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Fig. 1. Progression-free survival (PFS) for all patients (n = 18)
Survival time (years)
p = 0.01
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PFS were statistically significant even in such a small group 
(Fig. 3, p = 0.01 in Gehan’s Wilcoxon test). There was no 
statistically significant difference in PFS between patients 
previously consolidated in CR and in PR; however, only cas-
es with adequate nodal response (lymph node diameter 
< 5 cm) qualified. Similarly, bone marrow involvement had 
no impact on PFS and OS; however, only patients with lym-
phoma infiltration of less than 15% were included. The use 
of rituximab with previous chemotherapy regimens seems 
to have no impact on PFS; however, it is difficult to draw 
reliable conclusions from such a small group.
Hematologic toxicity
Hematologic toxicity was the main adverse event. Inci-
dences of grade 3–4 thrombocytopenia (n = 10, 56% cas-
es), neutropenia (n = 7, 39% cases) and anemia (n = 7, 39% 
cases) were observed. Five patients (27%) received gran-
ulocyte colony-stimulating factors, eight patients (44%) 
received platelet transfusions and six patients (33%) re-
ceived red blood cell transfusions.
Although recovery of platelet count, neutrophil count and 
hemoglobin concentration to normal levels took relatively 
long (57.5 days, 70.5 days and 83.5 days, respectively), there 
were no cases of hemorrhagic diathesis and the incidence 
of severe infection (grade 3–4) was low. Only three patients 
developed infections requiring hospital admissions: neutro-
penic fever of unknown origin, oral mucosa candidiasis and 
sepsis due to Streptococcus. None of them were fatal. 
Discussion
Radioimmunotherapy (RIT) has recently become a valu-
able treatment option for B-cell lymphomas. The combi-
nation of an anti-CD 20 monoclonal antibody (MoAb) 
with a radioisotope (Ibritumomab Tiuxetan with 90Y or 
Tositumomab with 131I) may damage B-cell lymphoma cells 
more effectively than monotherapy with rituximab alone. 
A single particle of MoAb conjugated with radionuclides 
may be effective against several neoplastic cells as a result 
of the crossfire effect [10], while several hundred naked 
MoAb are necessary to eliminate a single neoplastic cell. 
The effectiveness of ibritumomab tiuxetan radiolabelled 
with 90Y (Zevalin), as a consolidation therapy in follicular 
lymphoma (FL) has been proven in numerous clinical stud-
ies,evidenced by increased response rates and prolonged 
PFS [11–13]. Zevalin was registered for the treatment of 
recurrent or refractory follicular lymphoma. It should be 
emphasized that it is currently the only drug registered in 
Europe for rituximab refractory cases. Encouraging results 
of RIT in low grade lymphomas led to its investigation as 
a possible therapy in aggressive non-Hodgkin’s lympho-
ma (NHL). Although high-dose chemotherapy followed by 
peripheral stem cell transplantation is a recommended 
standard in cases with a partial response or relapsing high 
grade NHL, many patients don’t qualify for this procedure 
due to advanced age or comorbidities. RIT may be an inter-
esting alternative in this group of patients.
Preliminary results from other studies also suggest pos-
sible benefits of 90Y-IT, such as overall response rates rang-
ing from 58% to 78.6% (associated CR of 32–40%) with an 
estimated 2-year PFS of 75–85% [14–17]. Our observations 
showed that RIT consolidation improved the quality of re-
sponse, converting PR to CR in nearly 45% of cases (ranging 
from 38% to 83%). Median OS and PFS had not yet been 
reached at 5 years, while projected OS and PFS were 56% 
and 82%, respectively. Our patients could neither be sub-
jected to ASCT consolidation, nor continue their last che-
motherapy protocol (it was either completed or premature-
ly stopped due to toxicity or complications). Additionally, 
all patients were complete or partial responders according 
to Cheson criteria. In responsive patients, the tumor bur-
den, bone marrow involvement, clinical stage of lymphoma 
(II vs. III and IV), and IPI (0–2 vs. 3–5) at diagnosis had no 
prognostic significance on a response after RIT consolida-
tion. Similarly, we couldn’t demonstrate the impact of dis-
ease status at the time of RIT, since the response (CR vs. 
PR), diameter of the largest lymph nodes (less than 2 cm vs. 
2–5 cm) and bone marrow involvement (absent vs. present) 
did not significantly influence PFS. However, it should be 
noted that sample size was too small for any meaningful 
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Fig. 2. Overall survival (OS) for all patients (n = 18) 
Survival time (years)
p = 0.01
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Fig. 3. Comparison of progression-free survival of DLBCL patients 
consolidated by radioimmunotherapy in first and subsequent ther-
apy lines 
Survival time (years)
p = 0.01
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analysis and only responsive patients with low tumor bur-
den (maximal lymph node diameter < 5 cm and bone mar-
row involvement < 15%) were subjected to RIT. Our results 
are not fully consistent with other reports [16, 18]. 
In a retrospective study of 28 NHL patients subjected to 
RIT [16], the extent of lymphoma infiltration was evaluat-
ed on pre-therapy 111In-ibritumomab scans. A higher rate 
of complete response after 90Y-ibritumomab treatment 
was seen in patients with negative 111In-ibritumomab 
findings, raising questions of its diagnostic role. A better 
response was observed, the sooner RIT was started. The 
median duration of PFS has not been reached after 5 years 
of observation in patients consolidated in first-line thera-
py compared to 8 months in those consolidated in first or 
subsequent relapses. Similar results have been presented 
by Emmanouilides et al. [19]. 
In 211 patients with relapsed B-cell NHL (FL, DLBCL) 
where RIT was used as a chemotherapy consolidation, 
a higher percentage of CR and a longer median PFS were 
obtained at first relapse compared with patients treated 
after two or more lines (49% vs. 28% and 12.6 months vs. 
7.9 months, respectively). 
In a phase II prospective study published by Mor- 
schhauser et al. [15], the response to Zevalin in relapsing 
patients depended on prior usage of rituximab: OS and 
PFS were significantly longer in patients relapsing after 
CHOP compared to R-CHOP therapy (21.4 months vs. 4.6 
months and 5.9 months vs. 1.6 months, respectively). Such 
diminished responses in patients relapsing after initial 
R-CHOP are also observed after ASCT salvage therapy. We 
haven’t seen such a difference; however, RIT was given as 
a consolidation to chemo-sensitive patients with a small 
tumor burden and not as a sole treatment in relapsing/
refractory cases. RIT efficacy has been previously demon-
strated in rituximab resistant cases of DLBCL (44% RR in-
cluding 27% CR [20]) and FL (77% RR, 15% CR [21]); howev-
er, a small tumor burden seems to be crucial for long term 
efficacy. Efficacy of RIT in were further confirmed in recent 
publication, where RIT was used in previously untreated 
FL patients, in IIBX- IV-th clinical stage: ORR – 94%, me-
dian 3-year estimated PFS and OS rate 63·4% and 90%, 
respectively [22]. 
In most patients, the only significant adverse events 
were due to hematological toxicity manifesting as neutro-
penia and thrombocytopenia. Grade 3 and 4 toxicity were 
relatively common (39% and 56%, respectively); however, 
only three patients had infections that required hospital-
ization and there were no reported cases of bleeding di-
athesis. Hence, myelosuppression after RIT, although fre-
quent, was predictable and manageable. 
In conclusion, analysis of our study results confirms 
the efficacy of 90Y-IT consolidation treatment for refractory 
and recurrent DLBCL. 90Y-IT is well tolerated with manage-
able side effects. We did not find a relationship between 
the clinical stage of DLBCL at diagnosis and response to 
90Y-IT. Response to induction chemotherapy preceding 90Y-
IT does not have an impact on its effectiveness as a treat-
ment option. The lesser the time between initial DLBCL di-
agnosis and 90Y-IT usage, the more efficient the treatment. 
Given these results, early usage of 90Y-IT as a consolidation 
of first-line treatment, even in patients with PR, seems to 
be the most beneficial. 
The authors declare no conflict of interest.
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